TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01837966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender oil
Description: 2 drops for aromatherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 drops unscented mineral oil for aromatherapy
Study: NCT02931175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH gel
Description: Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH gel
Description: Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
Study: NCT01187836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV120027
Description: Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 14 hours.
Study: NCT00369967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: Initiation of NuvaRing for contraception

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Description: Initiation of NuvaRing for contraception
Study: NCT01675258

Intervention type: OTHER
Intervention: Salivary samples
Description: Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.

Intervention type: OTHER
Intervention: Salivary samples
Description: Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
Study: NCT01558986

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Patients received sterile water only within 30 minutes prior to skin incision
Study: NCT00708188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multidetector raw CT
Description: Multidetector raw CT
Study: NCT00480077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )
Description: OptiVol® Fluid status Monitoring with Cardiac Compass

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )
Description: OptiVol® Fluid status Monitoring with Cardiac Compass
Study: NCT04626180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extubation
Description: Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation
Description: Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Hyperinflation
Description: Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
Study: NCT02799589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
Study: NCT01830348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSC127
Description: DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vehicle gel
Study: NCT02321605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-BPS
Description: Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Activities
Description: Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
Study: NCT04487197

Intervention type: PROCEDURE
Intervention: blood sample for seroepidemiological investigation
Description: blood sample for seroepidemiological investigation

Intervention type: PROCEDURE
Intervention: blood sample for seroepidemiological investigation
Description: blood sample for seroepidemiological investigation
Study: NCT04154605

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClariFix cryotherapy
Description: Bilateral freeze ablation of nasal tissue using the ClariFix device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ClariFix cryotherapy
Description: Bilateral sham ablation procedure using the ClariFix device.
Study: NCT03345303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib Injectable Solution
Study: NCT04892030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Food Plant-Based Behavioral Weight Loss Treatment
Description: Over the course of 12-weeks, participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies through an e-learning platform. Each week, participants will also complete a 15-minute coaching call to provide positive reinforcement and problem-solving support.
Study: NCT01371058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high maintenance clopidogrel
Description: clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine dual antiplatelet
Description: clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: policosanol plus dual antiplatelet
Description: aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
Study: NCT02171143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2409
Description: intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous (IV)
Study: NCT03305952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Study: NCT00437268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
Study: NCT00283946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem MR
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Oral
Study: NCT04176393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivosidenib
Description: subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
Study: NCT02269696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Intraoperative metoprolol infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equal of volume compared to metoprolol.
Study: NCT00038948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Study: NCT04451408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372993
Description: Administered IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372993
Description: Administered IV or SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV or SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV or SC.
Study: NCT02101281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20 µg/mL
Description: 1 drop for each eye, twice daily for 28 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 4 µg/mL
Description: 1 drop each eye, twice daily for 28 day
Study: NCT04431375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir \[antiviral\] 300mg PO once a day .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir \[antiviral\] 300mg PO once a day .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Mircobiota Transplantation
Description: FMT for 7 days
Study: NCT06258824

Intervention type: DIAGNOSTIC_TEST
Intervention: Small RNA Sequencing and Validation of candidate miRNAs
Description: Samples were prepared for small RNA sequencing using Qiagen's QIAseq small RNA Library Prep kit, quality controlled using an Agilent Bioanalyzer 2100 and sequenced on an NextSeq 500 system (Illumina, San Diego, USA) using the default single-end 75 base pair protocol to include integrated unique molecular indices (UMIs). Validation was undertaken using Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) either using target-specific stem-loop primer assays (TaqMan) or universal reverse transcription (RT) and locked nucleic acid (LNA) enhanced specific primers with SYBR green I assay detection
Study: NCT01326806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together
Description: The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control on Hygiene & Nutrition
Description: The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
Study: NCT04505150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle changes, e.g., take part in regular exercise, quitting smoking, and reduce salt consumption
Description: Intervention participants will receive ongoing counselling with evidence-based information with pictures, fact sheets, published literature about the harmful effect of smoking on hypertension and other cardiovascular diseases for the cessation of smoking and to take part in regular exercise.
Study: NCT00516984

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No-touch control condition applied while subject was at a 50-degree head-up tilt.
Study: NCT04665804

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Supplementation
Description: Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine and Chondroitin sulfate supplementation
Description: Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise training
Description: Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise training
Description: Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: 2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: 2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy + Heating
Description: Interferential Current therapy (2P), in combination with heating pad for 20 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy + Heating
Description: Interferential Current therapy (2P), in combination with heating pad for 20 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
Study: NCT00516984

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
Study: NCT04665804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
Study: NCT01890265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamrevlumab
Description: Solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Study: Pirfenidone
Description: Pirfenidone concomitant therapy will not be provided by the Sponsor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sub-Study: Pirfenidone
Description: Pirfenidone concomitant therapy will not be provided by the Sponsor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Study: Nintedanib
Description: Nintedanib concomitant therapy will not be provided by the Sponsor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sub-Study: Nintedanib
Description: Nintedanib concomitant therapy will not be provided by the Sponsor.
Study: NCT04054336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibit AAT
Description: Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: classical AAT
Description: Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
Study: NCT00516984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMT
Description: Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
Study: NCT00863980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micardis (Telmisartan)
Description: 40-80 mg/day oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blopress (Candesartan)
Description: 8-12 mg/day oral administration
Study: NCT00460837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bowel preparation: senna & gastrofin versus picolax (standard)
Description: The intervention is a bowel cleansing procedure
Study: NCT04054336

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
Study: NCT03929666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25 (Zanidatamab)
Description: * Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25 (Zanidatamab)
Description: * Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25 (Zanidatamab)
Description: * Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25 (Zanidatamab)
Description: * Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally twice daily (PO bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered IV
Study: NCT00554138

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 dd for 7-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 1 dd 20 mg for 7-10 days
Study: NCT03929666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study: NCT04271475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Participants will receive Macitentan film-coated tablets orally od.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Participants will receive Macitentan film-coated tablets orally od.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive matching placebo tablets orally od.